Molecular Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2021-11-24 lmtjmu

一点消息没有啊两月过去了

54 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2019-04-16 OnJuly20th

我是Molecular Oncology的审稿人，审过它2篇文章

163 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2020-08-21 zhanyu

送审前被拒的概率有多大？

111 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2020-08-19 zhanyu

Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？

121 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2023-08-01 ms1000000321922839

建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。

69 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2021-05-30 fangchao1989

审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0
偏重的研究方向：肿瘤血管发育
经验分享：刚接收1篇，前期投Cancer Research不中投过来的
1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多
补实验2月，5.15修回，5.28接收
WB会要求原始曝光图及实验相关信息

76 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2021-12-20 阳关月

审稿速度:2.0 | 投稿命中率:25.0
经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择

66 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2019-03-26 trytofly

同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表:
你的咋样啦？大概initial check几天后送审？

steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？

179 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2023-08-07 blwu 来自广东省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗?

43 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1073634, encodeId=05c110e3634ef, content=一点消息没有啊两月过去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Wed Nov 24 21:17:16 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569595, encodeId=64e75695950a, content=我是Molecular Oncology的审稿人，审过它2篇文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5561608462, createdName=OnJuly20th, createdTime=Tue Apr 16 15:23:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811928, encodeId=fc2281192855, content=送审前被拒的概率有多大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Fri Aug 21 23:04:24 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811226, encodeId=41e38112267d, content=Awaiting AE Assignment，同时有EIC和3个ADM，以为着什么马上under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Wed Aug 19 23:47:38 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150760, encodeId=22a42150e6049, content=建议慎投，一审大修，二审（2同意发表，1问题较多），直接拒了，文章明明按问题多的审稿人解决了，二审的时候还提出来，编辑也不仔细看，反正一言难尽。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff056514044, createdName=ms1000000321922839, createdTime=Tue Aug 01 13:28:33 CST 2023, time=2023-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969727, encodeId=e73c969e273b, content=审稿速度:1.0 | 投稿命中率:75.0 | 版面费用:3600.0 偏重的研究方向：肿瘤血管发育 经验分享：刚接收1篇，前期投Cancer Research不中投过来的 1.21投稿，3.2Major，3个reviewer，1一个小修接收，一个正常评审，一个问题较多 补实验2月，5.15修回，5.28接收 WB会要求原始曝光图及实验相关信息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac4999328, createdName=fangchao1989, createdTime=Sun May 30 23:47:54 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082042, encodeId=761a1082042a6, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：杂志比较难得投，所有的都需要原图，wb可能要全膜，谨慎选择, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95db5541159, createdName=阳关月, createdTime=Mon Dec 20 11:17:44 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=568659, encodeId=f01e568659fd, content=同问，一般initial checking几天呀steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, beContent=steph 2019-01-11 00:00:00 发表: 你的咋样啦？大概initial check几天后送审？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=179, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1be91933436, createdName=trytofly, createdTime=Tue Mar 26 00:00:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151589, encodeId=3d6f2151589c0, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问在这个杂志，如何提交WB的原始图片? 每个图都必须有泳道的标记吗? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=34fa4692405, createdName=blwu, createdTime=Mon Aug 07 10:31:26 CST 2023, time=2023-08-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=582589, encodeId=12c458258929, content=这个杂志接收后需要提供原始曝光图吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23d05177737, createdName=向快乐出发, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]

2020-01-03 向快乐出发

这个杂志接收后需要提供原始曝光图吗？

134 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务